Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA (Pegloticase) (MIRROR Open-Label [OL])

Next Previous
Trial Profile

A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA (Pegloticase) (MIRROR Open-Label [OL])

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methotrexate (Primary) ; Pegloticase (Primary) ; Folic acid
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms MIRROR; MIRROR OL
  • Sponsors Horizon Pharma Rheumatology; Horizon Therapeutics plc

    • Most Recent Events

    • 15 Nov 2023 Results of analysis assessing potential baseline factors that may influence urate-lowering response to pegloticas using data from Phase 3 pegloticase registration and MIRROR RCT2 trials presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of post-hoc pooled analysis of C0405, C0406, MIRROR OL and MIRROR RCT trials assessing cardiovascular /thromboembolic events after pegloticase initiation, presented at the ACR Convergence 2023.
    • 02 Nov 2023 According to an Amgen media release, data from this study will be presented at the American Society of Nephrology Kidney Week, in Philadelphia.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top